U.S. markets close in 2 hours 9 minutes
  • S&P 500

    4,277.97
    +3.93 (+0.09%)
     
  • Dow 30

    33,893.27
    -87.05 (-0.26%)
     
  • Nasdaq

    12,972.51
    +34.39 (+0.27%)
     
  • Russell 2000

    1,989.55
    +2.23 (+0.11%)
     
  • Crude Oil

    91.32
    +3.21 (+3.64%)
     
  • Gold

    1,771.50
    -5.20 (-0.29%)
     
  • Silver

    19.46
    -0.27 (-1.37%)
     
  • EUR/USD

    1.0086
    -0.0094 (-0.93%)
     
  • 10-Yr Bond

    2.8840
    -0.0090 (-0.31%)
     
  • GBP/USD

    1.1930
    -0.0121 (-1.01%)
     
  • USD/JPY

    135.8910
    +0.8010 (+0.59%)
     
  • BTC-USD

    23,375.47
    -38.29 (-0.16%)
     
  • CMC Crypto 200

    558.01
    +0.28 (+0.05%)
     
  • FTSE 100

    7,541.85
    +26.10 (+0.35%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Wellspring Ophthalmics Announces Receiving Its Second Patent for Novel Cyclosporine Dry Eye Therapy

·2 min read

Company Remains Focused on Finding a Licensee for This Proprietary Cyclosporine Platform and is Encouraged by the Significant Interest to Date

MISSION VIEJO, Calif., July 20, 2022--(BUSINESS WIRE)--Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy, announces receiving its second patent for a novel cyclosporine dry eye therapy. The Company’s intellectual property portfolio, which includes additional pending patents, covers a broad formulation platform of a unique suspension comprising aqueous, amorphous nanodispersions of cyclosporine. This new patent and the Company’s formulation platform strengthens the foundation for an entry into the global over $1.5 billion dry eye prescription eye drops market.

Dry eye remains under-diagnosed and under-treated -- about 30 million people in the U.S. suffer from dry eye, but only about half are diagnosed and only about 1.7 million people in the U.S. are treated with prescription eye drops. Today’s branded and generic prescription cyclosporine products are mostly emulsions, which have been shown to have low bioavailability in the eye and to produce poor patient outcomes. Wellspring Ophthalmics’ flexible formulation platform overcomes known deficiencies of current cyclosporine eye drops because it is designed to have higher bioavailability for better efficacy and improved dry eye relief.

"The addition of a second issued patent to our intellectual property portfolio adds more protection and value for the right development and commercialization partner to deliver an unmatched therapy to countless dry eye sufferers," said Orlando Rodrigues, Co-founder, CEO and President of Wellspring Ophthalmics. "Based on the significant interest we’ve received to date, we are confident and enthused we will engage the right licensing partner near-term, so the work to bring this exciting dry eye innovation to market can continue."

Wellspring Ophthalmics continues seeking a licensee who will complete development and commercialize its newly acquired innovative platform.

About Wellspring Ophthalmics

Wellspring Ophthalmics, Inc. is a development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy by unlocking the power of cyclosporine for superior dry eye relief. The Company owns the patent portfolio for a novel dry eye therapy comprising a broad formulation platform for a unique suspension containing aqueous, amorphous nanodispersions of cyclosporine. Wellspring Ophthalmics aims to license its intellectual property portfolio, including issued and pending patents, to a licensee who will complete development of and commercialize its innovation.

For more information, please visit www.wellspringdryeye.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005929/en/

Contacts

Orlando Rodrigues
Wellspring Ophthalmics, Inc.
760.212.5727
orlando@wellspringdryeye.com